U.S. Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Fine-needle Aspiration, Core, Surgical, Skin Biopsy/Punch Biopsy), By Application, By Site, And Segment Forecasts, 2023 - 2030

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Research Methodology
• 1.2 Research Assumptions
  • 1.2.1 Estimates And Forecast Timeline
• 1.3 Research Methodology
• 1.4 Information Procurement
  • 1.4.1 Purchased Database
  • 1.4.2 Gvr's Internal Database
  • 1.4.3 Secondary Sources
    • 1.4.3.1 Primary Research
  • 1.4.4 Details Of Primary Research
• 1.5 Information Or Data Analysis
  • 1.5.1 Data Analysis Models
    • 1.5.1.1 End-Use Landscape Assessment
    • 1.5.1.2 Market Origin Assessment
    • 1.5.1.3 Oncology Diagnosis: Market Competition Analysis
• 1.6 Market Formulation And Validation
• 1.7 Model Details
  • 1.7.1 Commodity Flow Analysis
    • 1.7.1.1 Approach 1: Commodity Flow Approach
    • 1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
• 1.8 U.S. Market: CAGR Calculation
• 1.9 List of Secondary Sources
• 1.10 List of Primary Sources
• 1.11 Objectives
  • 1.11.1 Objective 1
  • 1.11.2 Objective 2
  • 1.11.3 Objective 3
  • 1.11.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Outlook

Chapter 3 Market Variables, Trends, and Scope

• 3.1 Cancer Medical Tourism Within & Outside the U.S.
• 3.2 Market Driver Analysis
  • 3.2.1 Advent Of Liquid Biopsy
  • 3.2.2 Transition Of Novel Oncology Diagnostics From Bench To Clinics
  • 3.2.3 Advancements In Quality And Payment Pertaining To Genetic Cancer Tests
• 3.3 Market Restraint Analysis
  • 3.3.1 Risks Associated With Biopsy Procedures
  • 3.3.2 Technical And Clinical Challenges
• 3.4 Market Opportunity Analysis
  • 3.4.1 Integral Role Of Biopsies In Oncology Companion Diagnostics
  • 3.4.2 Increase In The Demand For Biopsies In Translational Research
• 3.5 Market Threat Analysis
  • 3.5.1 Risk Associated With Repeat Biopsy Procedures

Chapter 4 Business Environment Analysis

• 4.1 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
• 4.2 Porter's Five Forces Analysis

Chapter 5 Supply Chain Analysis

• 5.1 Sample Collection (List of Biobanks/Center)
• 5.2 Sample Processing (List of Vendors)

Chapter 6 Cost/Pricing Analysis

• 6.1 Biopsy Cost
  • 6.1.1 By Indication
    • 6.1.1.1 Typical Biopsy Costs For Patients Not Covered By Health Insurance In The U.S.
  • 6.1.2 By Type/Method
• 6.2 Key Factors Influencing The Cost
• 6.3 Costs Of Cancer Management
  • 6.3.1 Pharma Versus Diagnostics Price Analysis For Cancer Care
  • 6.3.2 U.S. Expenditures For Cancer By Source Of Payment
    • 6.3.2.1 Expenditures For Cancer Care By Year & Cancer Site, USD Million, 2010 - 2018

Chapter 7 Reimbursement And Regulatory Analysis

• 7.1 Regulatory Framework: U.S. Cancer Biopsy Market
• 7.2 Reimbursement Framework: U.S. Cancer Biopsy Market

Chapter 8 Challenges/Restraints/Complications Analysis

• 8.1 Challenges/Restraints/Complications Analysis
  • 8.1.1 By Site (Organ)
  • 8.1.2 By Method

Chapter 9 Cancer Biopsy Product Manufacturers

Chapter 10 Type Business Analysis

• 10.1 U.S. Cancer Biopsy Market: Type Movement Analysis
• 10.2 U.S. Cancer Biopsy Market: Comparative Analysis of Biopsy Type
• 10.3 Fine Needle Aspiration
• 10.4 Core Needle Biopsy (CNB)
  • 10.4.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.4.1.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
    • 10.4.1.2 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
• 10.5 Cancer Surgical Biopsy
  • 10.5.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.5.1.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
    • 10.5.1.2 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
• 10.6 Skin Biopsy/Punch Biopsy
  • 10.6.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.6.1.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
    • 10.6.1.2 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
    • 10.6.1.3 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.6.1.4 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
    • 10.6.1.5 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
• 10.7 Others
  • 10.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Types, 2018 - 2030 (USD Million)
    • 10.7.1.1 U.S. other types cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
    • 10.7.1.2 U.S. other types cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)

Chapter 11 Site (Organ) Business Analysis

• 11.1 Cancer Biopsy Market: Site (Organ) Movement Analysis
• 11.2 Breast
  • 11.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Breast, 2018 - 2030 (USD Million)
• 11.3 Thyroid
  • 11.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Thyroid, 2018 - 2030 (USD Million)
• 11.4 Uterus & Cervix
  • 11.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Uterus & Cervix, 2018 - 2030 (USD Million)
• 11.5 Lung
  • 11.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Lung, 2018 - 2030 (USD Million)
• 11.6 Prostate
  • 11.6.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Prostate, 2018 - 2030 (USD Million)
• 11.7 Bladder
  • 11.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Bladder, 2018 - 2030 (USD Million)
• 11.8 Kidney
  • 11.8.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Kidney, 2018 - 2030 (USD Million)
• 11.9 Liver
  • 11.9.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Liver, 2018 - 2030 (USD Million)
• 11.10 Pancreas
  • 11.10.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pancreas, 2018 - 2030 (USD Million)
• 11.11 Other Sites
  • 11.11.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Sites, 2018 - 2030 (USD Million)

Chapter 12 Application (Cause) Business Analysis

• 12.1 U.S. Cancer Biopsy Market: Application (Cause) Movement Analysis
• 12.2 Screening & Monitoring
  • 12.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Screening & Monitoring, 2018 - 2030 (USD Million)
• 12.3 Diagnostics
  • 12.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Diagnostics, 2018 - 2030 (USD Million)
• 12.4 Investigational & Translational Research
  • 12.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Investigational & Translational Research, 2018 - 2030 (USD Million)
• 12.5 Pharma & Biopharma Discovery & Development
  • 12.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pharma & Biopharma Discovery & Development, 2018 - 2030 (USD Million)

Chapter 13 Regional Business Analysis

• 13.1 U.S. Cancer Biopsy Market: Regional Movement Analysis
• 13.2 U.S.
  • 13.2.1 U.S. Cancer Biopsy Market, 2018 - 2030 (USD Million)

Chapter 14 Competitive Landscape

• 14.1 Market Participation Categorization
• 14.2 Strategy Framework
• 14.3 Vendor Landscape
  • 14.3.1 List Of Key Distributors And Channel Partners
  • 14.3.2 Key Customers
    • 14.3.2.1 List Of Key Customers
  • 14.3.3 Public Companies
    • 14.3.3.1 List Of Public Companies
  • 14.3.4 Private Companies
    • 14.3.4.1 List Of Key Private Companies
  • 14.3.5 Emerging Players
    • 14.3.5.1 List Of Key Emerging Companies
• 14.4 Major Deals And Strategic Alliances Analysis
  • 14.4.1 Mergers And Acquisitions
  • 14.4.2 Collaborations And Partnerships
  • 14.4.3 New Product Launch
• 14.5 Market Impact Analysis By Key Participants
  • 14.5.1 Ansoff Matrix
  • 14.5.2 Company/Competition Categorization (Primary & Secondary Market Participants)

Chapter 15 Company Profiles

• 15.1 Company Profiles
  • 15.1.1 Bd (Becton, Dickinson And Company)
    • 15.1.1.1 Company Overview
    • 15.1.1.2 Financial Performance
    • 15.1.1.3 Product Benchmarking
    • 15.1.1.4 Strategic Initiatives
  • 15.1.2 Izi Medical Products
    • 15.1.2.1 Company Overview
    • 15.1.2.2 Product Benchmarking
    • 15.1.2.3 Strategic Initiatives
  • 15.1.3 Johnson & Johnson Services, Inc.
    • 15.1.3.1 Company Overview
    • 15.1.3.2 Depuy Synthes
    • 15.1.3.2.1 Company Overview
    • 15.1.3.3 Ethicon, Inc.
    • 15.1.3.3.1 Company Overview
    • 15.1.3.4 Financial Performance
    • 15.1.3.5 Product Benchmarking
  • 15.1.4 Argon Medical
    • 15.1.4.1 Company Overview
    • 15.1.4.2 Product Benchmarking
    • 15.1.4.3 Cook
    • 15.1.4.4 Company Overview
    • 15.1.4.5 Product Benchmarking
  • 15.1.5 Spectra Medical Devices, Inc.
    • 15.1.5.1 Company Overview
    • 15.1.5.2 Product Benchmarking
  • 15.1.6 Medtronic
    • 15.1.6.1 Company Overview
    • 15.1.6.2 Financial Performance
    • 15.1.6.3 Product Benchmarking
    • 15.1.6.4 Strategic Initiatives
  • 15.1.7 Boston Scientific Corporation
    • 15.1.7.1 Company Overview
    • 15.1.7.2 Financial Performance
    • 15.1.7.3 Product Benchmarking
    • 15.1.7.4 Strategic Initiatives
  • 15.1.8 Conmed Corporation
    • 15.1.8.1 Company Overview
    • 15.1.8.2 Financial Performance
    • 15.1.8.3 Product Benchmarking
  • 15.1.9 Inrad, Inc.
    • 15.1.9.1 Company Overview
    • 15.1.9.2 Product Benchmarking
  • 15.1.10 Thermo Fisher Scientific, Inc.
    • 15.1.10.1 Company Overview
    • 15.1.10.2 Financial Performance
    • 15.1.10.3 Product Benchmarking
    • 15.1.10.4 Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 Reasons for the popularity of oncology tourism in some countries
• Table 3 Common types of oncology tourism treatments
• Table 4 Liquid biopsy developing or commercializing companies
• Table 5 Average pricing analysis: Biopsy to indication
• Table 6 Average pricing analysis: Biopsy to indication
• Table 7 Expenditures for cancer care by year & cancer site, USD Million, 2010 - 2018
• Table 8 List of cleared/approved companion diagnostic devices (In vitro and imaging tools)
• Table 9 Types of insurance coverage
• Table 10 Policy structure types issued by private payers and Medicare
• Table 11 Coverage policies for ctDNA
• Table 12 CPT codes for minimally invasive prostate procedures
• Table 13 CPT codes for office visits-new & established patient
• Table 14 Surgical biopsy: Feasibility analysis across cancer diagnosis
• Table 15 Comparative analysis of traditional and liquid liver biopsies

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 End-use landscape: Cancer biopsy product penetration
• Fig. 5 Cancer biopsy: Market origin/parent market assessment
• Fig. 6 Market competition analysis: Early diagnosis industry sector
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. cancer biopsy market outlook (2022)
• Fig. 9 U.S. cancer biopsy market driver impact
• Fig. 10 External factors driving the demand for cancer biopsy
• Fig. 11 U.S. cancer biopsy market restraint impact
• Fig. 12 SWOT analysis
• Fig. 13 Porter's five forces analysis
• Fig. 14 Key driving factors of biopsy costs
• Fig. 15 U.S. expenditures for cancer by payment source, 2018
• Fig. 16 National cancer costs projected to increase drastically by 2030, in USD Billion
• Fig. 17 U.S. out-of-pocket expenses 2014 vs. 2018
• Fig. 18 U.S. cancer management expenditure
• Fig. 19 U.S. cancer biopsy market: Type outlook and key takeaways
• Fig. 20 U.S. cancer biopsy market: Type movement analysis
• Fig. 21 Tissue biopsy vs liquid biopsy: Comparative analysis
• Fig. 22 U.S. cancer core needle biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 U.S. cancer core needle biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
• Fig. 24 U.S. cancer core needle biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
• Fig. 25 U.S. cancer surgical biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 U.S. cancer surgical biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
• Fig. 27 U.S. cancer surgical biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
• Fig. 28 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
• Fig. 30 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
• Fig. 31 U.S. skin biopsy/punch cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 U. S .skin biopsy /punch cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
• Fig. 33 U.S. skin biopsy /punch cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
• Fig. 34 U.S. cancer liquid biopsy market estimates and forecasts for other types, 2018 - 2030 (USD Million)
• Fig. 35 U.S. other types of cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
• Fig. 36 U.S. other types of cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
• Fig. 37 Cancer biopsy market: Site (Organ) outlook and key takeaways
• Fig. 38 Cancer biopsy market: Site (Organ) movement analysis
• Fig. 39 U.S. cancer biopsy market estimates and forecasts for breast, 2018 - 2030 (USD Million)
• Fig. 40 U.S. cancer biopsy market estimates and forecasts for thyroid, 2018 - 2030 (USD Million)
• Fig. 41 U.S. cancer biopsy market estimates and forecasts for uterus & cervix, 2018 - 2030 (USD Million)
• Fig. 42 U.S. cancer biopsy market estimates and forecasts for lung, 2018 - 2030 (USD Million)
• Fig. 43 U.S. cancer biopsy market estimates and forecasts for prostate, 2018 - 2030 (USD Million)
• Fig. 44 U.S. cancer biopsy market estimates and forecasts for bladder, 2018 - 2030 (USD Million)
• Fig. 45 U.S. cancer biopsy market estimates and forecasts for kidney, 2018 - 2030 (USD Million)
• Fig. 46 U.S. cancer biopsy market estimates and forecasts for liver, 2018 - 2030 (USD Million)
• Fig. 47 U.S. cancer biopsy market estimates and forecasts for pancreas, 2018 - 2030 (USD Million)
• Fig. 48 U.S. cancer biopsy market estimates and forecasts for other sites, 2018 - 2030 (USD Million)
• Fig. 49 U.S. cancer biopsy market: Application (Cause) outlook and key takeaways
• Fig. 50 U.S. cancer biopsy market: Application (Cause) movement analysis
• Fig. 51 U.S. cancer biopsy market estimates and forecasts for screening & monitoring, 2018 - 2030 (USD Million)
• Fig. 52 U.S. cancer biopsy market estimates and forecasts for diagnostics, 2018 - 2030 (USD Million)
• Fig. 53 U.S. cancer biopsy market estimates and forecasts for investigational & translational research, 2018 - 2030 (USD Million)
• Fig. 54 U.S. cancer biopsy market estimates and forecasts for pharma & biopharma discovery & development, 2018 - 2030 (USD Million)
• Fig. 55 U.S. cancer biopsy market, 2018 - 2030 (USD million)
• Fig. 56 Participant categorization - U.S. cancer biopsy market
• Fig. 57 Strategy framework - U.S. cancer biopsy market
• Fig. 58 Ansoff matrix
• Fig. 59 Competition categorization